
Pulmatrix Releases Q3 2024 Financial Results and Corporate Update
Pulmatrix Releases Q3 2024 Financial Results and Corporate Update Description Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology. Pursuing strategic alternatives to further leverage iSPERSE™ and optimize the potential of PUR3100. Completed PUR1900 wind down activities. Cash runway projected into Q4 2026. FRAMINGHAM, Mass., Nov. 8, 2024 /PRNewswire/ — Pulmatrix, Inc….